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The present status of investigations about the anticancer activity which is inherent to medicinal mushrooms, as well as their bio-
medical potential and future prospects are discussed. Mushroom products and extracts possess promising immunomodulating and 
anticancer effects, so the main biologically active substances of mushrooms responsible for immunomodulation and direct cytoto-
xicity toward cancer cell lines (including rarely mentioned groups of anticancer mushroom proteins), and the mechanisms of their 
antitumor action were analyzed. The existing to date clinical trials of mushroom substances are mentioned. Mushroom anticancer 
extracts, obtained by the different solvents, are outlined. Modern approaches of cancer treatment with implication of mushroom 
products, including DNA vaccinotherapy with mushroom immunomodulatory adjuvants, creation of prodrugs with mushroom 
lectins that can recognize glycoconjugates on the cancer cell surface, development of nanovectors etc. are discussed. The future 
prospects of mushroom anticancer substances application, including chemical modification of polysaccharides and terpenoids, gene 
engineering of proteins, and implementation of vaccines are reviewed.
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INTRODUCTION
The most recent approaches in cancer treatment 
include construction of nanovectors for drug-delivery and 
diagnostics [1], design of prodrugs that can be  converted 
to active form when targeting tumor cells [2], gene 
therapy [3], and other methods which have an impact 
on malignant cells but don’t affect normal cells. These 
technologies are more effective in the early stages 
of the disease, and the best result is achieved when com-
bined with classical chemotherapy and radiotherapy [3]. 
Thus, chemotherapy counts more than 100 anticancer 
drugs with different mechanism of action. Numerous 
side effects of chemo- and radiotherapy require the use 
of additional remedies to maintain and improve the im-
mune status of patients. For instance, anticancer therapy 
can include the use of herbal drugs, especially those 
that have cytotoxic properties with minimal side effects. 
Mushrooms attract more and more interest as a raw 
material for the production of such drugs. Therapeutic 
properties of medicinal mushrooms were exploited 
by folk medicine throughout the world since ancient 
times [4]. Nowadays about 14 thousand of mushroom 
species are known [5]. There are different data about 
the number of mushroom species possessing anticancer 
activity: from 200 to 331 (out of 540 mushroom species 
which are used in China medicinal practice) [6]. After 
analyzing of these mushroom species one can say that 
150 of them are inherent to Ukraine.
Numerous investigators appealed to Macromycetes 
in urge to find efficient herbal remedies for anticancer 
therapy. So, the determination of the present status 
of investigations about the anticancer activity of medici-
nal mushrooms, their biomedical potential and future 
prospects of usage are important and urgent.
ANTICANCER SUBSTANCES 
OF MUSHROOM ORIGIN
Biologically active substances of medicinal mush-
rooms with anticancer action comprise polysaccha-
rides, polysaccharide-protein complexes, dietary 
fiber, certain types of proteins, terpenoids, steroids, 
phenols, etc.
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Abbreviations used: Bcl-X(L) — B-cell lymphoma (extra-large) 
transmembrane molecule in the mitochondria; ED50 — effective dose 
for 50% of the group; EGF — epidermal growth factor; Fas/APO-1 – 
apoptosis antigen 1; GTP — guanosine triphosphate; HMAF – 6-hy-
droxymethylacylfulvene; HPV — human papillomavirus; IC50 — half 
maximal inhibitory concentration; IFN — interferon; IL — interleukin; 
IκВα – nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha; NF-κB — nuclear factor kappa-light-chain-
enhancer of activated B cells; PSK — polysaccharide K; PSP — poly-
saccharide peptide; TGF — transforming growth factor; TNF — tumor 
necrosis factor; Th — T helper cells.
Cell lines and tumor strains: А549 — human lung epithelial carci-
noma; Bre-04 — human breast carcinoma; В16 – murine melanoma; 
CAL27 — human oral cancer; CCD 841 CoTr — normal human colon 
epithelium; СН72 — murine skin carcinoma; colon 26-L5 — murine 
liver metastatic carcinoma; С50 — normal mouse skin keratinocytes; 
Ehrlich’s carcinoma — mouse breast carcinoma; HeLa – human 
cervical cancer; Hep G2 — human liver carcinoma; HL-60 — human 
promyelocytic leukemia; HPAF-II – human pancreatic adenocarci-
noma; HTC — rat liver carcinoma; НТ-29 — human colon adenocarci-
noma; HT-1080 — human fibrosarcoma; Huh-7 — human hepatoma; 
Jurkat — human T cell leukemia; К562 — human myelogenous eryth-
roleukemia; LLC – Lewis lung carcinoma; LS180 — human colon 
adenocarcinoma; Lu-04 — human lung carcinoma; L1210 — mouse 
lymphocytic leukemia; MCF-7 — human breast adenocarcinoma; 
MDA-MB — human mammary gland adenocarcinoma; MV522 — hu-
man lung carcinoma; МХ-1 – human ductal breast adenocarcinoma; 
PC-3 – human prostate cancer; PLC/PRF/5 — (Alexander) human 
hepatoma; PL45 — human pancreatic epithelial adenocarcinoma; 
Р388 — murine lymphocytic leukemia; RPMI-8226 — human my-
eloma; T24 — human urinary bladder carcinoma; T-47D — human 
ductal breast epithelial tumor; Vero — monkey kidney normal cells; 
WI-38 – human lung fibroblast; WM-1341 – human melanoma.
Exp Oncol 2014
36, 2, 58–66
REVIEW
Experimental Oncology 36, 58–66, 2014 (June) 59
Polysaccharides and polysaccharide-protein 
complexes
Biologically active polysaccharides were detected 
in fruiting bodies, mycelial mass and cultural broth 
of Macromycetes. Mushroom polysaccharides pre-
vent carcinogenesis and metastasis, and, in addition, 
display immune cell-mediated anticancer activity [7]. 
Polysaccharides with antitumor activity belong pre-
dominantly to glucans with β-(1→3) bonds in the main 
chain and with β-(1→3) bond side branches, wherein 
side branches are essential for occurrence of biologi-
cal activity. Furthermore, it was demonstrated [8] that 
high-molecular weight polysaccharides are more ef-
ficient than low-molecular. It is generally recognized 
that application of mushroom polysaccharides can 
be an additional remedy for cancer patient’s treat-
ment, but it is reasonable to combine such agents 
with traditional methods of therapy like surgery, 
chemo- and radiotherapy [3]. In such combination 
polysaccharides, polysaccharide-protein complexes, 
and mushroom extracts have an ability to reduce side 
effects of conventional cancer treatments [8]. Worth 
to note, that clinical trials of mushroom origin drugs 
are sufficiently expensive and long-term. Therefore, 
there are plenty investigations of medicinal mushroom 
anticancer activity in vitro and in vivo, but, to the best 
of our knowledge, read by the number polysaccharides 
and polysaccharide-protein complexes have passed 
clinical trials (Table 1). Mentioned in the Table 1 sub-
stances have undergone clinical trials I–III phases 
in Japan, China, and USA. Initial phases of clinical tri-
als have shown anticancer activity of these drugs and 
absence of short-term or long-term toxicity, as well [8].
Table 1. Mushroom antitumor polysaccharide and polysaccharide-protein 
complexes which have passed clinical trials
Taxa Origin of isolation Trade name Chemical structure Ref.
Grifola fron-
dosa
Fruiting bodies 
and mycelium
D and MD-
fractions
β-D-glucan [7]
Lentinus 
edodes
Fruiting bodies Lentinan β-D-glucan [8]
Schizophyllum 
commune
Cultured broth Schizophyllan β-D-glucan [8]
Trametes ver-
sicolor
Mycelial mass PSP, PSK 
(Krestin)
Polysaccharide-
protein complexes
[8]
Lentinan (see Table 1) is a water-soluble antican-
cer polysaccharide, which was isolated from fruiting 
bodies of L. edodes by Chihara et al. [9] in 1969. 
Lentinan has a molecular weight 500 kDa, the main 
chain consists of glucose, connected with β-(1→3) 
bonds, and side chains, connected with main chain 
by β-(1→6) bonds. Lentinan binds to lymphocyte 
cell surface or to specific proteins of blood serum 
which activate macrophage, T-killers, and other ef-
fector cells that, in turn, enhance antibody, IL-1, IL-2, 
and IFN-γ production. Lentinan completely inhibits 
the growth of subcutaneously transplanted in mice 
Sarcoma-180 [4]. In clinical trials [10] after the admini-
stration of tegafur to patients, suffering from gastric 
cancer, the survival rates increased during the first 
and second years at the same level (2.9%), though 
du ring the third year an increase in survival rate was not 
observed. Patients who had been treated with tegafur 
in combination with lentinan, during 1, 2, and 3 years 
(1 mg twice a week or 2 mg once a week administered 
intravenously) showed survival rate increases by 19.5; 
10.4, and 6.5%, respectively. Similar results were ob-
tained in case of progressive and relapsing rectal can-
cer [11]. At the same time, administration of lentinan 
in combination with anticancer drugs mitomycin C and 
5-fluorouracil didn’t lead to any positive results. If com-
bined lentinan with radiotherapy and surgery, a positive 
effect was achieved in treatment of lung, breast, and 
gastric cancer [11]. Adverse reactions and toxicity 
of lentinan were observed in rare cases [4].
The structure and anticancer activity of schizophyl-
lan (see Table 1) are similar to lentinan [8]. Schizo-
phyllan is a (1→3)-β-glucan in linear linkage with 
(1→6)-β-glucopyranoside branches, bonded to every 
third or fourth residue [12]. Schizophyllan restores and 
enhances cellular immunity in the tumor-bearing host 
by functioning as a T-cell adjuvant and macrophage 
activator; it also induces the gene expression of cyto-
kines [12]. In in vivo studies [12] schizophyllan inhibits 
solid Sarcoma 180 and increases survival of mice when 
injected by intraperitoneal or intravenous route, but has 
low antitumor activity by subcutaneous route. It also has 
no effect on the survival of mice bearing Sarcoma 37, 
Ehrlich’s carcinoma, or Yoshida sarcoma [12]. Clinical 
studies with schizophyllan in combination with con-
ventional chemotherapy (tegafur or mitomycin C and 
5-fluorouracil) in a randomized study of 367 patients 
with recurrent and inoperable gastric cancer resulted 
in a significant increase in median survival [8]. Recently 
it has also been shown, that schizophyllan increases 
overall survival of patients with head and neck can-
cers [8]. In a randomized study, schizophyllan, in com-
bination with radiotherapy, significantly prolonged the 
overall survival of stage II cervical cancer patients but 
not stage III [8]. Schizophyllan is currently produced 
commercially by several Japanese pharmaceutical 
companies and approved for clinical use in Japan.
Two different polysaccharide fractions with anti-
cancer properties were obtained from mycelial mass 
of basidiomycete T. versicolor. PSK (krestin) is a β-D-
glucan-protein complex which was obtained by Japan 
company “Kureha Kagaku Koguo K.K.” by the method 
of hot water extraction [13]. Mechanism of krestin anti-
cancer activity involves the following actions: recovery 
from immunosuppression induced by humoral factors 
such as TGF-β or as a result of surgery and chemo-
therapy; activation of antitumor immune responses 
including maturation of dendritic cells, correction 
of Th1/Th2 imbalance, promotion of IL-15 production 
by monocytes; and enhancement of the antitumor 
effect of chemotherapy by induction of apoptosis 
and inhibition of metastasis through direct actions 
on tumor cells [14].
The researchers of the Shanghai University (China) 
have isolated the substance named PSP (consists 
of 90% polysaccharide and 10% of protein, mo-
lecular weight is about 100 kDa) from mycelial mass 
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of T.  versicolor Cov-1 [13]. The protein part is com-
posed of asparagines and glutamic acid, the main 
component of polysaccharide is glucose in the main 
chain, which is bonded with α-(1→4) and β-(1→3) 
glycoside linkages. The chemical structure of PSP 
is similar to PSK, but the former contains fucose, and 
the latter — arabinose and rhamnose [15].
970 patients took part in clinical trial of PSP has been 
performed by Yang et al. [15]. 485 tumor patients were 
given PSP along with chemo- and radiotherapy in this 
research; control tests were made of 211 cases; random 
groups were selected for forward-expecting and dou-
ble-blind control tests from the remaining 274 ca ses. 
Various kinds of cancer were involved in the study: gas-
tric (162 cases), esophagus (172 cases), and primary 
pathogenic lung cancer (151 cases). Tested group was 
treated with 3 g of PSP daily over two periods with dura-
tion of one month. The number of cases of increased 
natural killer cell activity, of increased IL-2, and CD4+/
CD8+ ratio was more than observed in the control group. 
Addition of PSP lowered side effects of chemo- and 
radiotherapy, appreciable relief was evident especially 
in the cases of poor appetite, weakness, tiredness, dry-
ness of mouth and throat, and pain. Quality of tumorous 
patients’ life improved on parameters of body weight 
and Karnofsky’s evaluation.
Polysaccharide fractions of G. frondosa were 
also extensively investigated. D-fraction of hot water 
deproteinated extract from both the fruiting bodies 
and mycelia of G. frondosa consists predominantly 
of β-D-glucan with 1→6 bonds in the main chain and 
1→4 branches or 1→3 bonds in the main chain and 
1→6 branches [8]. Mechanism of D-fraction action 
includes activation of macrophages, which, in turn, 
increase the production of cytokines. D-fraction 
of G. frondosa appears to inactivate glyoxalase I in in vi-
tro studies, an enzyme believed to metabolize chemo-
therapeutic compounds used against cancer cells thus 
potentially enhancing their bioavailability [8]. The MD-
fraction has been obtained by further purification of the 
D-fraction and showed a superior anti-cancer effect. 
The MD-fraction can induce cancer cell apoptosis 
via activation of the BAK-1 gene [16]. The combina-
tion of IFN-α2b and the MD-fraction has been shown 
to have a synergistic effect that triggers DNA-depen-
dent protein kinase activation and induces cancer 
cell arrest at the G1 cell cycle checkpoint. The D- and 
MD-fractions are undergoing phase  I/ II clinical trials 
in the United States and Japan [16].
There are some methods of anticancer activity 
and clinical quality intensification for polysaccharide 
remedies. Thus, carboxymethylated, hydroxylated, 
formylmethylated, aminethylated and sulfated pro-
ducts have been designed to improve the biological 
activity by chemical modification. Particularly, the line-
ar (1→3)-α-glucans from Amanita muscaria and Ag-
rocybe cylindracea have little antitumor activity, but 
the carboxymethylated linear (1→3)-α-glucan showed 
high potent antitumor activity against Sarcoma 180 and 
immunomodulatory activity in mice [12].
Mushroom anticancer proteins
Mushroom polysaccharides are the most exten-
sively investigated among all the bioactive substances 
of mushrooms. However, bioactive proteins constitute 
another important part of functional components 
in mushrooms, which also attract increasing attention 
due to their pharmaceutical potential and possibility 
to apply protein engineering with specified properties. 
Mushroom proteins with anticancer activity can be di-
vided by two groups: proteins with direct antiprolifera-
tive activity on cancer cells and immunomodulating 
proteins. Lectins form a group which can possess 
both mechanisms of action. Cancer cell lines Hep 
G2 and MCF-7 have been used the most frequently 
for examination of mushroom proteins antiproliferative 
activity in vitro (Table 2).
Table 2. Cytotoxicity of mushroom proteins against tumor cell lines
Protein group Taxa ІС50 for tumor cell lines, μM Ref.Hep G2 MCF-7
Lectin Pholiota adiposa 2.1 3.2 [17]
Hericium erinaceum 56.1 76.5 [18]
Russula lepida 1.6 0.9 [19]
Russula delica 0.88 0.52 [20]
Laccase Tricholoma mongolicum 0.65 1.4 [21]
Clitocybe maxima 12.3 3.0 [22]
Abortiporus biennis 12.5 6.7 [23]
Agrocybe cylindracea 5.6 6.5 [24]
Hericium coralloides > 60.0 [25]
Ribosome inac-
tivating protein
Hypsizigus marmoreus 0.15 5.0 [26]
Lectins are multivalent proteins or glycoproteins 
of nonimmune origin, which can specifically reco-
gnize and reversibly bind to carbohydrate moiety 
of glycoconjugates without disturbing the covalent 
structure of any recognized glycoside ligand [27]. Bio-
logical role of lectins is very diverse: they participate 
in the mobilization and transportation of sugars, cell 
recognition, growth regulation, and differentiation, 
as well as in the process of the penetration of parasitic 
fungi into a host organism and in the relation between 
the fungal organism and a higher plant in the process 
of mycorrhization [27]. Lectins are probably the most 
extensively investigated of all the mushroom pro-
teins. It is worth to note that owing to unique capacity 
of specifically binding to glycoconjugates, mushroom 
lectins find applications in study of the modifications 
in membrane glycoconjugates and cancer formation, 
sorting of mutant and tumor cells, diagnostics, and 
creation of prodrugs. Apart from cell agglutinating 
activity, some lectins possess mitogenic activity toward 
certain cell types, e. g., immune cells, and/or direct 
antiproliferative activity toward tumor cells [28].
Among lectins with direct cytotoxicity against can-
cer cells mention may be made of ricin B-like lectin 
from Clitocybe nebularis that can recognize human 
blood group A determinant carbohydrates and pos-
sesses antiproliferative activity specific to human 
leukemic T cells [28]. Belonging to the same type 
glycoprotein lectin from fruiting bodies of G.  frondosa 
is cytotoxic against HeLa cells [29]. Lectins from 
Polyporus adusta and Ganoderma carpense exhibit 
both mitogenic activity toward spleen cells and an-
tiproliferative activity toward cancer cells [29]. Anti-
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proliferative activity of some lectins toward human cell 
lines Hep G2 and MCF-7 is summarized in the Table 2.
At the same time, some mushroom lectins appertain 
to a new family of bioactive proteins which is referred 
to as fungal immunomodulatory proteins. Thus, a fun-
gal immunomodulatory lectin referred to as fve from 
Flammulina velutipes demonstrated potent adjuvant 
properties enhancing T-helper type 1 antigen-specific 
and peripheral blood lymphocyte immune responses, 
thus leading to strong antitumor effect [29]. It also 
was shown that fve could enhance INF-γ production 
via the p38-mitogen activated protein kinase signaling 
pathway which is considered being the key factor for 
antitumor activity of fve in vivo.
Another immunomodulatory lectin was isolated 
from the fruiting bodies of A. cylindracea and showed 
a six-fold increase in mitogenic response when mouse 
splenocytes were incubated with 2 μM of aforemen-
tioned lectin [29]. Bolesatine is a toxic glycoprotein 
from Boletus satanas with hemagglutinating acti vity 
which displays biphasic action: mitogenic activity to-
ward human and rat lymphocytes at low doses and in-
hibiting effect at higher doses. It also elicits the release 
of IL-1 and IL-2 in supernatants from mononuclear 
cell cultures [30]. Lectin from Volvariella volvacea 
expresses mitogenic activity toward human peri pheral 
lymphocytes, inhibits generation of bovine serum 
albumin-induced Arthus reaction, and stimulates 
transcriptional expression of IL-3, IL-4, IFN-γ, TNF-α, 
lymphotoxin, and IL 2-receptor [29].
Lin et al. [29] isolated an immunomodulatory 
protein of non-lectin origin GMI from Ganoderma mi-
crosporum and investigated its activity in suppressing 
tumor invasion and metastasis. It was found that GMI, 
in a dose-dependent manner, inhibits EGF mediated 
migration and invasion in A549 cells by several path-
ways such as inhibiting EGF-induced phosphorylation, 
EGF-induced activation of Cdc42 GTPase, activation 
of EGF receptor and Ala pathway kinases.
Hemolysin is an agent or a substance that causes 
the destruction of red blood cells, thereby liberating 
hemoglobin [31]. Thereby, hemolysin can be distin-
guished similarly to lectin namely by interaction with 
red blood cells. Few hemolytic proteins isolated from 
mushrooms, among them hemolysins from Pleurotus 
ostreatus, Pleurotus eryngii, Pleurotus nebrodensis, 
and Amanita phalloides, exhibited potential anti-proli-
ferative activity on several cancer cell lines in vitro [32]. 
Thus, phallolysin from A. phalloides is cytotoxic to HeLa 
cells and ascites tumor cells (the mouse sarcoma 
P43), P. ostreatus hemolysin possess antiproliferative 
activities against HT-1080 and MCF-7 cells, P. eryngii 
hemolysin reduces the viability of L1210 cells, finally, 
nebrodeolysin from P. nebrodensis showed strong 
cytotoxicity against Lu-04, Bre-04, HepG2, L929 and 
HeLa cells with apoptosis induction in L929 and HeLa 
cells [32].
Laccases deserve special interest among mush-
room enzymes because of their potent role in the bio-
degradation of lignin and phenolic pollutants. In addi-
tion, recently was found that some mushroom laccases 
possess direct cytotoxicity in vitro, particularly toward 
Hep G2 and MCF-7 cell lines (see Table 2). Laccases 
(benzenediol: oxygen oxidoreductase) form a class 
of ligninolytic enzymes which demonstrate a rather 
low degree of specificity with regard to the reducing 
substrate: they catalyze the oxidation of ortho- and 
para-diphenols and aromatic amines by  removing 
an electron and a proton from a hydroxyl group 
to generate a free radical [29]. It is likely that cytoto-
xicity of laccases can be associated with their capacity 
to oxidize wide range of substrates.
Recently was shown that antiproliferative activity can 
be attributed to enzymes which inactivate ribosomes 
by eliminating one or more adenosine residues from 
rRNA [28]. During the past decade, mushroom ribosome 
inactivating proteins were isolated from se veral species 
including Calvatia caelata, F. velutipes, H. marmoreus, 
Lyophyllum shimeiji, and Pleurotus tuber-regium [28]. 
Thus, calcaelin from C. caelata demonstated anti-mito-
genic activity toward spleen cells and anti-proliferative 
activity toward breast cancer cells [29].
Ribonucleases distinct from ubiquitin-like peptides 
and proteins were isolated from several mushroom 
species. One of RNase was isolated from Pleurotus 
sajor-caju; it exerts an antiproliferative action on hepa-
toma and leukemia cells, and anti-mitogenic action 
on mouse spleen cells [29].
Ubiquitin-conjugated proteins including cell cycle 
regulatory proteins, p53 tumor suppressor, the trans-
criptional regulator NF-κB and its inhibitor, numerous 
transcription factors, and the mos protooncogen, 
are targets for degradation by the 26S proteasome. 
The ubiquitin-mediated pathway regulates cell-cycle 
progression, signal transcription regulation, receptor 
down-regulation, endocytosis, immune response, 
development, and apoptosis. Defects in ubiquitin-
mediated events may be involved in the development 
of pathological conditions including malignant trans-
formation [29]. Particularly, ubiquitin-like peptide from 
the mushroom C. caelata demonstrates anti-mitogenic 
activity toward mouse splenocytes and antiproliferative 
activity toward human breast cancer cells [29]. Similarly, 
the ubiquitin-like peptide from A. cylindracea exerts 
immunostimulating and antiproliferative activities [29].
Antifungal protein lentin was isolated from fru iting 
bodies of L. edodes. It was shown [33] that lentin 
exhibited cytotoxicity toward cell line L1210 with 
IC50 0.2 μM supposedly via inhibition of translation.
Cytotoxic terpenoids from mushrooms
Terpenoid is any of a class of hydrocarbons that 
consist of terpenes attached to an oxygen-containing 
group [31]. In turn, terpene is any from the class of hy-
drocarbons consisting of two or more isoprene (C5H8) 
units joined together [31].
Numerous investigations are devoted to cytotoxic 
activity of basidiomycete Ganoderma lucidum triter-
penoids (containing 6 isoprene units). More than 
150 triterpenoids were isolated from fruiting bodi-
es of the genus Ganoderma [34]. Polyoxygenated 
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 gano deric triterpene acids T, V, W, X, Y, and Z with la-
nostane skeleton, isolated from G. lucidum, exhibi ted 
cytotoxic activity in vitro toward HTC cell line [35]. It was 
shown [36] that triterpenoid fraction from the fruiting 
bodies of G. lucidum contains ganoderic acid F and 
exhibits anticancer and antimetastatic activity through 
inhibition of angiogenesis which was induced by tumor. 
Triterpene enriched fraction from G. lucidum mycelium 
inhibited the growth of Huh-7 cells with IC50 about 
100 μg/ml, though showed low toxicity (IC50 > 1 mg/ml) 
for normal hepatocytes [37]. This fraction inhibited 
protein kinase C, but activated other protein kinases 
(which is usually occurs during mitosis) and arrested 
cell cycle in G2 phase in the hepatoma cells, however 
it didn’t have such effect in normal hepatocytes [37]. 
Previously it was shown that the mechanism of this 
fraction cytotoxicity for tumor cells includes oxidative 
stress [38]. Three triterpene aldehydes with lanostane 
skeleton were derivated from fruiting bodies of G. luci-
dum and named lucialdehydes A, B, and C [39]. Luci-
aldehydes B and C exhibited cytoto xicity toward LLC, 
T-47D, Sarcoma 180 and Sarcoma Meth-A cell lines. 
Lucialdehyde C revealed the highest cytotoxicity to-
ward tested cells with ED50 10.7, 4.7, 7.1, and 3.8 mg/l, 
respectively. It was eluci dated [40], that intracellular 
triterpenoids from G. lucidum can be produced pre-
dominantly on the latter stages of submerged fermen-
tation, have different composition and cytotoxicity 
toward K562 cells.
Mushroom terpenoids can be cytotoxic not 
only for cancer cells, but also for normal cells; 
therefore creation of semisynthetic analogues with 
specified pro perties is a promising approach. Thus, 
in 1963 as a result of screening from about 600 mush-
rooms it was determined [41] that Lampteromyces 
japonicus has a high anticancer activity associated 
with toxic substance lamterol. Cytotoxic tricyclic ses-
quiterpene (containing 3 isoprene units) illudin S 
(lamterol) can be also synthesized by Omphalotus 
olearius [4]. It is believed that illudin S undergoes 
activation by glutathione. The activated form is then 
capable of covalently bind to DNA which halts DNA 
replication  [4] and leads to cell death in interphase 
G1-S [42]. Illudin S itself is too toxic to be used 
as a clinical drug. Consequently, a semisynthetic illudin 
analog HMAF, that demonstrated a superior therapeu-
tic profile and lower toxicity, employed in clinical trials. 
In vitro investigations of HMAF have shown that IC50 for 
cancer cell lines ranging from 160 nM in sensitive 
MCF-7 to 17 μM in relatively insensitive B16 cells [43]. 
In vivo antitumor activity was consistent with in vitro 
sensitivity. HMAF was very effective in human tumor 
xenograft models, including MX-1, MV522, and HT-29, 
but not B16 or P388 [43]. Thus, complete regression 
recorded in 29 of 30 animals bearing MX-1 tumors af-
ter administration of HMAF intravenously at the doses 
of 3–7.5 mg/kg daily for 5 days. Extensive tumor 
shrinkage was also observed with MV522, and sig-
nificant tumor growth inhibition was obtained with 
HT-29 when animals received intraperitoneal injections 
at the doses ranging from 3.75 to 7.5 mg/kg during 
5 days [43]. Complete regressions were also observed 
in individual animals with MV522 and HT-29. HMAF 
passed successfully clinical trial phase I [44], though 
during the phase II the lack of efficiency was re-
vealed [45, 46], and subsequent studies have stopped.
Anticancer activity of mushroom steroids, 
phenols, and dietary fiber
Among mushroom steroids the glycosylated form 
of ergosterol peroxide from the methanol extract 
of Cordyceps sinensis was found [47] to be an inhibitor 
of proliferation of K562, Jurkat, WM-1341, HL-60, and 
RPMI-8226 tumor cell lines.
Anticancer sterol from Sarcodon aspratus selec-
tively suppressed the growth of HT29 cancer cells, but 
not WI38 normal human fibroblasts [48]. Investigations 
of anticancer mechanism have shown that aforemen-
tioned sterol induces expression of the cyclin-depen-
dent kinase inhibitor 1A, thus causing cell cycle arrest 
and apoptosis in HT29 cells.
Phenols can possess anticancer activity as pre-
ventive agent with antioxidant properties and also 
can exhibit direct cytotoxicity toward cancer cells. 
Thus, hericenones A and B from Hericium erinaceum 
demonstrated complete growth inhibition of HeLa cells 
at the concentrations of 100 μg/ml and 6.3 μg/ml re-
spectively [49]. It was suggested, that potent cyto-
toxicity of hericenone B may be due to γ-lactam and 
its N-substituent.
Mushroom cell walls contain high molecular weight 
materials which cannot be digested or absorbed by hu-
man intestine, but absorb carcinogenic substances 
(heavy metals, free radicals, etc.): chitin, homo- and 
heteropolysaccharides [4].
Quantitative and qualitative composition of fungal 
mycelia depends on various cultivation conditions, 
especially on the substrate for cultivation. Synthetic 
easily accessible media can suppress generation 
of some valuable secondary metabolites [50]. In this 
aspect the selection of the cultivation media is one 
of the important stages for obtaining of biologically 
active substances of fungal mycelia. The most pre-
ferred can be considered natural substrates — wastes 
of agriculture [51].
ANTICANCER EXTRACTS FROM 
MUSHROOMS
The above substances having antitumor activity 
were extracted from the fungi with various solvents. 
Ethanol, methanol, ethyl acetate, and hot water ex-
tracts of fruiting bodies and mycelia are often used 
in preclinical studies of mushroom antitumor activity 
in vitro and in vivo. Occasionally anticancer activity 
of other extracts (acetone, ether, chloroform, cold 
water, etc.) has been tested.
The first demonstration of mushroom extract an-
titumor activity has been conducted in 1957 by Lucas 
et al. [52] using extracts from the fruiting bodies of Bo-
letus edulis and other holobasidiomycetes against 
Sarcoma-180.
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Ethanol extracts
Among mushroom extracts an ethanol extract 
probably finds the most extensive application. Thus, 
ethanol extracts of Pleurotus florida and Calocybe 
indica caused apoptosis in T24 cell line in the dose-
dependent manner [53].
The effects of ethanol extracts from G. frondosa, 
G. lucidum, Hericium erinaceus, and L. edodes 
fru iting bodies, spores, and cultured broth were as-
sessed for modulation of cell proliferation and apop-
tosis in CH72 cancer cells and C50 normal cells [54]. 
Among above-listed ethanol extracts only L. edodes 
extract significantly decreased CH72 cell prolifera-
tion; at the same time, none of the extracts changed 
proliferative response of normal C50 cells. Cell cycle 
analysis de monstrated that L. edodes extract induced 
a transient G1 phase arrest in CH72 cells.
It was demonstrated [55], that A. brasiliensis 50% 
ethanol extract in concentration 0.9 mg/ml and hot 
water extract in concentration 0.7 mg/ml caused 
morphological changes and significantly reduced 
CAL27 cell viability after 48-h treatment. Both extracts 
induced apoptotic cell death in CAL27 via the release 
of cytochrome c from mitochondria into the cytoplasm 
and activation of caspase-3 in vitro.
Comparison of the effects of extracellular, intracel-
lular polysaccharides, and ethanol extracts of Tremella 
mesenterica revealed [56] that only ethanol extract 
induced apoptosis in A549 cells. Such effect was pro-
voked by activating a mitochondrial pathway: disruption 
of mitochondrial transmembrane potential, the produc-
tion of reactive oxygen species, and the activation of cas-
pase-3 protein in ethanol extract-treated A549 cells.
Methanol extracts
The methanol extracts of Pleurotus ostreatus and 
Pleurotus salmoneostramineus showed suppressive 
effect against growth of HT-29 cell line with survival 
rates of 39.9 and 40.7% at the concentration 500 μg/ml, 
while survival rate was more than 50% when Pleurotus 
cornucopiae methanol extract was employed [57].
Anticancer activity can be not only species-, but 
also a strain-dependent characteristic. This point 
of view was illustrated by another study dedicated 
to comparison of antiproliferative activity of metha-
nol extracts from European and Asian G. lucidum 
[58]. The research revealed that methanol extract 
of Chinese strain as opposite to French strains 
didn’t inhibit the growth of HT29 cell line. However, 
all investigated extracts exhibited different cytotoxic 
activity (with IC50 varied from 68 to 171 μg/ml) toward 
PC-3 and MCF7 cell lines. It was established [58] that 
methanol extracts of G. lucidum contain triterpenoids 
which apparently can cause apoptosis of cancer cells.
Ethyl acetate extracts
One of the studies [59] was associated with anti-
proliferative activity of ethyl acetate and culture broth 
extracts of Coprinus comatus. The investigation 
showed that IC50 value for MCF7 cells was 76  μg/ ml for 
culture broth extract and 32 μg/ml for ethyl acetate 
extract. The results also revealed that both extracts 
significantly affected IκВα phosphorylation in a dose-
dependent manner. In addition, the data obtained 
showed that only ethyl acetate extracts inhibited 
the activity of IκВ kinase enzyme complex at close 
to 90% as compared to the control of the untreated 
sample.
Ethyl acetate extract from Antrodia camphorata 
fruiting bodies decreased the cell growth of Hep G2 and 
PLC/PRF/5 cells in a dose dependent manner [60]. 
In Fas/APO-1 positive-Hep G2 cells, extract increased 
the expression level of Fas/APO-1 and its two forms 
of ligands, membrane-bound Fas ligand and soluble 
Fas ligand, in a p53-indenpendent manner. In addi-
tion, extract also initiated mitochondrial apoptotic 
pathway through regulation of Bcl-2 family proteins 
expression, release of cytochrome c, and activation 
of caspase-9 both in Hep G2 and PLC/PRF/5 cells. 
Furthermore, it also inhibited the cell survival sig-
naling by enhancing the amount of IκВα in cytoplasm 
and reducing the level and activity of NF-κB in the nu-
cleus, and subsequently attenuated the expression 
of  Bcl-X(L) in Hep G2 and PLC/PRF/5 cells.
Hot water extracts
Oral administration of mixture (known as M8) from 
hot water extracts of the 7 medicinal mushrooms 
(Armillaria mellea, G. frondosa, Garnoderma frondosa, 
Cordyceps militaris, Hericium erinaceus, T. versicolor, 
and Agaricus blazei) and the medicinal plant Lycium 
barbarum resulted in a dose-dependent tendency 
to inhibit lung metastasis after intravenous injection 
of colon26-L5 cells [61]. Treatment with M8 resulted 
in the increase of T cell and B cell mitogenic sti-
muli as well as in increased production of IFN-γ and 
IL-4 by splenocytes.
Hot water extract of Inonotus obliquus exerts inhibi-
tory activity against the proliferation of HT-29 in a dose-
dependent manner via the induction of apoptosis and 
inhibition of the cancer growth through up-regulation 
of the expression of proapoptotic proteins (bcl-2-like 
protein 4 and caspase-3) and down-regulation of an-
tiapoptotic protein Bcl-2 [62].
Other extracts
Acetone extracts of seven edible mushroom fru-
iting bodies (Hericium erinaceum, Lentinus lepides, 
Leucopaxillus giganteus, Lyophillum decastes, Pleu-
rocybella porrigens, Pleurotus cornucopiae, and 
Sarcodon aspratus) were tested against HL60 cell 
line [63]. Antiproliferative activity of the S. asparatus 
extract was the most prominent. The active substance 
ergosterol peroxide completely inhibited growth and 
induced apoptosis of HL60 cells at a concentration 
10.7 μg/ml.
Ether and ethanol extracts of Piptoporus betulinus 
mycelia highly decreased the viability of LS180 cancer 
cells, slightly inhibiting proliferation and tumor cell 
adhesion in a time- and dose-dependent manner [64]. 
At the same time, the cytotoxicity of the extracts 
against CCD 841 CoTr normal cells was observed only 
at the highest studied concentration.
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Ethanol, ethyl acetate, chloroform, and, in some 
cases, culture liquid extraction of 12 medicinal mush-
rooms were screened for their effect on the viability 
of HPAF-II and PL45 cell lines with various treatment 
doses (50–500 μg/ml) [65]. The best results were 
obtained for Cyathus striatus culture luquid extract, 
even at lower concentrations (1–50 μg/ml) it showed 
a significant decrease in cell viability.
To the best of our knowledge, there was no posi-
tive evidence of anticancer activity attributed to cold 
water extracts of medicinal mushrooms. Thus, cold 
water extract of Agaricus brasiliensis didn’t influence 
intestinal immunoglobulin A level or TNF-α, IFN-γ, and 
IL-10 levels in serum of experimentally immunode-
pressed mice with cyclophosphamide [66]. Though, 
cold water extracts of medicinal mushrooms can cause 
other effects, such as hepatoprotective [67].
NOVEL APPROACHES OF CANCER 
TREATMENT USING MUSHROOM 
PRODUCTS
Vaccinotherapy
Vaccine preparations with preventive properties 
against liver and cervical cancer associated with 
hepatitis B and human papillomatosis infections were 
developed in Belgium and USA [68]. At the same time, 
to date there is no vaccine on commercial scale aimed 
to cure existing tumors, metastases or relapses. Addi-
tion of immunomodulating substances of natural and 
synthetic origin to vaccines can sufficiently enhance 
their anticancer properties.
Thus, there were substantiated doses and schemes 
of L. edodes polysaccharide fraction administra-
tion along and design of it combination with vac-
cine on the basis of autological glycopeptides 
of Ehrlich’s carcinoma, Sarcoma 37, LLC, L1210, and 
B16 cell lines [68]. Such preparations enhance cyto-
lytic activity of lymphocytes, metabolic activity of peri-
toneal macrophages, and cytolytic activity of blood 
serum in the presence of complement in intact animals 
and in Sarcoma 37 bearing animals.
An immunomodulating protein Ling Zhi-8 from my-
celia of G. lucidum with stimulatory activity on dendritic 
cells was recently identified [69]. The large-scale am-
plification of recombinant protein Ling Zhi-8 has been 
achieved in a patented yeast system. It was shown [69] 
that aforementioned protein significantly increases 
the efficacy of a cancer DNA vaccine in a preclinical 
tumor model.
Nanovectors for drug delivery
Nowadays preparation of nanoparticles using 
“green” chemistry and bioprocess approach is advan-
tageous over physical and chemical methods owing 
to its environmental significance. In this aspect,  living 
organisms are highly potential for the production 
of nanoparticles. Irregular shaped gold nanoparticles 
were synthesized by photo-irradiation technique using 
Pleurotus florida as a reductant [70]. It was suggested 
that flavins (flavo proteins) present in the mushroom 
extract are responsible for the reduction of ions into 
nanoparticles: when exposed to sunlight flavins absorb 
photons of energy and can act in reduction-oxidation 
reactions. Obtained nanoparticles showed cytoto xicity 
against A-549, K-562, HeLa, and MDA-MB cancer 
cells and no effect against Vero normal cells.
CONCLUDING REMARKS
Analysis of literature data has shown that antican-
cer activity of mushroom products provoked increasing 
interest of researchers. The most abundant amount 
of investigations among anticancer substances 
of mushroom origin are attached to polysaccharides, 
polysaccharide-protein complexes, lectins and 
terpenoids. Only a few of substances has passed 
initial phases of clinical trials: D- and MD-fractions 
of G. frondosa, PSP and PSK from T. versicolor, len-
tinan from L. edodes, schizophyllan from S. commune, 
and HMAF from L. japonicus.
Mushroom lectins are a group of proteins which 
can possess as immunomodulating as well as direct 
cytotoxic activity toward cancer cells. It is also possible 
to use specificity of lectins to glucoconjugate in order 
to study the modifications in membrane glucoconju-
gates and cancer formation, sorting of mutant and tu-
mor cells, diagnostics, and creation of prodrugs. There 
are some rarely mentioned anticancer mushroom 
proteins as hemolysin proteins, enzyme laccase, ribo-
some inactivating proteins, and ubiquitin-conjugated 
proteins which display direct cytotoxic activity in vitro. 
Proteins can be a convenient tool for medical treatment 
because of the possibility of genetic engineering and 
large-scale amplification.
Anticancer activity of ethanol, methanol, ethyl 
acetate, and hot water extracts of fruiting bodies and 
mycelia from mushrooms of different ecological and 
systematical groups was established. Some examples 
of mushroom extracts investigations are provided.
Substances contained in mushrooms may be able 
to interfere with tumor through a variety of mecha-
nisms, e.g., by enhancing the host’s antioxidant 
capacity or by absorption of carcinogens. Yet other 
mushroom constituents may inhibit promotion or pro-
gression of cancer by exerting direct cytotoxic effects 
on tumor cells, by interfering with tumor angioge-
nesis, or by upregulating immune and/or non-immune 
tumor-suppressive mechanisms. When combined with 
traditional anticancer treatment, mushroom products 
were shown to lower side effects.
Vaccinotherapy is a new direction in cancer treat-
ment and prevention. In this aspect mushroom im-
munomodulating adjuvants can be an efficient com-
ponent of traditional and DNA vaccines.
Creation of nanovectors for drug delivery and 
diagnostic is also a new approach in cancer therapy. 
Mushroom mycelia can be an ecologically clean and 
efficient reductant in conversion of ions to nanopar-
ticles with selective cytotoxicity toward cancer cells.
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